肝癌分子分型指导精准诊断与治疗的研究前沿

肝癌未来数十年仍将是威胁我国人民生命健康的重大疾病。近年来,随着肝癌早诊早治、精准肝切除以及靶向和免疫治疗药物研发的进步,提高了肝癌患者的生存率。尽管如此,由于肝癌的高度异质性,同一临床分期的肝癌患者对治疗应答及预后仍存在很大差异,迫切需要新分期、分型指标以助力肝癌精准诊断与治疗,从而进一步提高患者生存率。多组学技术、单细胞技术、肿瘤分子可视化技术及医学人工智能等的不断进步和发展,使肝癌分子分型正越来越接近肿瘤生物学特征的真正本质,从而助力肝癌精准诊断与治疗的实施和健康中国的战略规划。

Research advances in molecular classification for precision diagnosis and treatment of hepatocellular carcinoma

Hepatocellular carcinoma(HCC),a highly prevalent malignancy and one of the leading cause of cancer death in China,remains a major public health problem in the next decades.Owing to the tremendous achievements in early diagnosis,precision liver surgery,molecular targeted therapy and immunotherapy,we have witnessed significant improvements in the long-time survival of HCC patients,if properly treated.However,HCC is a highly heterogeneous disease.Even for patients within the same clinical stage,their clinical outcome and treatment efficacy vary significantly.Great efforts to improve the molecular classification of HCC patients are needed to foster precision medicine,paving the way for novel therapeutic strategies.Advances in multi-omics,single-cell analysis,molecular imaging and artificial intelligence will lead to better understanding of the molecular classification and refine precision treatment in HCC,ultimately excluding this neoplasm from the risk list of our Healthy China.